EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00230568
- Lead Sponsor
- Eisai Inc.
- Brief Summary
12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method FOME (Fuld Object Memory Evaluation); SDMT (Symbol Digit Modalities Test); NPI (Neuropsychiatric Inventory); MMSE (the Mini-Mental State Examination). 12 weeks.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (33)
21st Century Neurology
🇺🇸Phoenix, Arizona, United States
Alzheimer's Disease and Cognitive Disorders Clinic at Barrow Neurology Institute
🇺🇸Phoenix, Arizona, United States
Pacific Sleep Medicine Services, Inc.
🇺🇸San Diego, California, United States
Parkinson's Disease Movement Disorders Center - Boca Raton
🇺🇸Boca Raton, Florida, United States
Bradenton Research Center
🇺🇸Bradenton, Florida, United States
MD Clinical
🇺🇸Hallandale Beach, Florida, United States
Eastern Research
🇺🇸Hialeah, Florida, United States
Berma Research Group
🇺🇸Hialeah, Florida, United States
Cuervo Research Group
🇺🇸Miami, Florida, United States
Seth Hochman, MD
🇺🇸Miami, Florida, United States
Scroll for more (23 remaining)21st Century Neurology🇺🇸Phoenix, Arizona, United States